CCL18 敲低抑制甲状腺癌细胞生长和迁移。
CCL18 Knockdown Suppresses Cell Growth and Migration in Thyroid Cancer.
机构信息
Department of Endocrinology, Yantaishan Hospital, Yantai 264000, China.
Family Planning Office, Rizhao Hospital of TCM, Rizhao 276800, China.
出版信息
J Healthc Eng. 2022 Jan 25;2022:1548155. doi: 10.1155/2022/1548155. eCollection 2022.
BACKGROUND
Chemokine (C-C motif) ligand 18 (CCL18) is a chemokine that plays a key role in immune and inflammatory responses. In recent years, CCL18 participates in the development and progression of various cancers, but its expression and role in thyroid cancer (TC) remain unclear.
METHODS
RT-qPCR assay and Western blot assay were used to explore the expression level of CCL18 in TC tissues and cells. Cell proliferation was measured by MTT assay. Transwell assay was adopted to detect cell migration in TC cells. Dual luciferase reporter assay was performed to assess the relationship between CCL18 and miR-149-5p.
RESULTS
There was an uptrend of CCL18 in TC tissues and cells. Our findings indicated that CCL18 overexpression facilitated lymph node metastasis in patients with TC. CCL18 silencing was found to inhibit cell migration, proliferation, and EMT progression in TC cells. CCL18 was proved to be a target gene of miR-149-5p. Additionally, miR-149-5p weakened the effect of CCL18 in the progression of TC.
CONCLUSION
Therefore, our results indicated that CCL18 knockdown restrained TC progression and suggested that CCL18 might be a potential therapeutic target for TC.
背景
趋化因子（C-C 基序）配体 18（CCL18）是一种在免疫和炎症反应中起关键作用的趋化因子。近年来，CCL18 参与了多种癌症的发生和发展，但它在甲状腺癌（TC）中的表达和作用尚不清楚。
方法
采用 RT-qPCR 检测和 Western blot 检测 CC18 在 TC 组织和细胞中的表达水平。采用 MTT 法检测细胞增殖。采用 Transwell 检测 TC 细胞的迁移。采用双荧光素酶报告基因检测评估 CCL18 与 miR-149-5p 之间的关系。
结果
CCL18 在 TC 组织和细胞中呈上升趋势。我们的研究结果表明，CCL18 过表达促进了 TC 患者的淋巴结转移。CCL18 沉默被发现抑制了 TC 细胞的迁移、增殖和 EMT 进展。CCL18 被证明是 miR-149-5p 的靶基因。此外，miR-149-5p 减弱了 CCL18 在 TC 进展中的作用。
结论
因此，我们的研究结果表明，CCL18 敲低抑制了 TC 的进展，并提示 CCL18 可能是 TC 的潜在治疗靶点。
Zotero 插件